243 related articles for article (PubMed ID: 32741705)
1. Domain-selective targeting of BET proteins in cancer and immunological diseases.
Petretich M; Demont EH; Grandi P
Curr Opin Chem Biol; 2020 Aug; 57():184-193. PubMed ID: 32741705
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Gilan O; Rioja I; Knezevic K; Bell MJ; Yeung MM; Harker NR; Lam EYN; Chung CW; Bamborough P; Petretich M; Urh M; Atkinson SJ; Bassil AK; Roberts EJ; Vassiliadis D; Burr ML; Preston AGS; Wellaway C; Werner T; Gray JR; Michon AM; Gobbetti T; Kumar V; Soden PE; Haynes A; Vappiani J; Tough DF; Taylor S; Dawson SJ; Bantscheff M; Lindon M; Drewes G; Demont EH; Daniels DL; Grandi P; Prinjha RK; Dawson MA
Science; 2020 Apr; 368(6489):387-394. PubMed ID: 32193360
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit.
Rianjongdee F; Atkinson SJ; Chung CW; Grandi P; Gray JRJ; Kaushansky LJ; Medeiros P; Messenger C; Phillipou A; Preston A; Prinjha RK; Rioja I; Satz AL; Taylor S; Wall ID; Watson RJ; Yao G; Demont EH
J Med Chem; 2021 Aug; 64(15):10806-10833. PubMed ID: 34251219
[TBL] [Abstract][Full Text] [Related]
5. Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.
Fu Y; Zhang Y; Sun H
Eur J Med Chem; 2021 Dec; 226():113853. PubMed ID: 34547507
[TBL] [Abstract][Full Text] [Related]
6. Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development.
Chen J; Tang P; Wang Y; Wang J; Yang C; Li Y; Yang G; Wu F; Zhang J; Ouyang L
J Med Chem; 2022 Apr; 65(7):5184-5211. PubMed ID: 35324195
[TBL] [Abstract][Full Text] [Related]
7. Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology.
Galdeano C; Ciulli A
Future Med Chem; 2016 Sep; 8(13):1655-80. PubMed ID: 27193077
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
Slavish PJ; Chi L; Yun MK; Tsurkan L; Martinez NE; Jonchere B; Chai SC; Connelly M; Waddell MB; Das S; Neale G; Li Z; Shadrick WR; Olsen RR; Freeman KW; Low JA; Price JE; Young BM; Bharatham N; Boyd VA; Yang J; Lee RE; Morfouace M; Roussel MF; Chen T; Savic D; Guy RK; White SW; Shelat AA; Potter PM
Cancer Res; 2020 Sep; 80(17):3507-3518. PubMed ID: 32651255
[TBL] [Abstract][Full Text] [Related]
10. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
12. Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors.
Aylott HE; Atkinson SJ; Bamborough P; Bassil A; Chung CW; Gordon L; Grandi P; Gray JRJ; Harrison LA; Hayhow TG; Messenger C; Mitchell D; Phillipou A; Preston A; Prinjha RK; Rianjongdee F; Rioja I; Seal JT; Wall ID; Watson RJ; Woolven JM; Demont EH
J Med Chem; 2021 Mar; 64(6):3249-3281. PubMed ID: 33662213
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective bivalent inhibitors of BET bromodomains.
Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y
Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins.
Yang Y; Wu Z; Chen P; Zheng P; Zhang H; Zhou J
Future Med Chem; 2020 Sep; 12(18):1669-1683. PubMed ID: 32893690
[TBL] [Abstract][Full Text] [Related]
15. RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
Jahagirdar R; Attwell S; Marusic S; Bendele A; Shenoy N; McLure KG; Gilham D; Norek K; Hansen HC; Yu R; Tobin J; Wagner GS; Young PR; Wong NCW; Kulikowski E
Mol Pharmacol; 2017 Dec; 92(6):694-706. PubMed ID: 28974538
[TBL] [Abstract][Full Text] [Related]
16. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
17. Bromodomain biology and drug discovery.
Zaware N; Zhou MM
Nat Struct Mol Biol; 2019 Oct; 26(10):870-879. PubMed ID: 31582847
[TBL] [Abstract][Full Text] [Related]
18. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Ramadoss M; Mahadevan V
Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
[TBL] [Abstract][Full Text] [Related]
19. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.
Liang D; Yu Y; Ma Z
Eur J Med Chem; 2020 Aug; 200():112426. PubMed ID: 32502863
[TBL] [Abstract][Full Text] [Related]
20. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
Chen D; Lu T; Yan Z; Lu W; Zhou F; Lyu X; Xu B; Jiang H; Chen K; Luo C; Zhao Y
Eur J Med Chem; 2019 Nov; 182():111633. PubMed ID: 31461688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
